NovoBiotic Pharmaceuticals

NovoBiotic Pharmaceuticals is a pioneering biotech company that has overcome a major bottleneck in natural product discovery by developing innovative culturing technologies, such as the iChip and diffusion chambers, to access the >99% of environmental microbes previously deemed unculturable. This platform has yielded a proprietary library of over 75,000 microbial isolates and led to the discovery of promising new antibiotic classes, most notably teixobactin and clovibactin, which are in late preclinical development. The company is strategically positioned to address the critical global need for novel antibiotics against multidrug-resistant pathogens, operating as a private, grant-funded entity with a lean team focused on advancing its pipeline.

Proprietary in situ cultivation technologies (diffusion chambers, iChip, 'trap' devices) to isolate and grow previously 'unculturable' environmental microorganisms, enabling natural product drug discovery from a novel library of over 75,000 microbial isolates.

NovoBiotic's core platform is differentiated by its physical cultivation of novel microbes, unlike metagenomic screening approaches. It competes with other biotechs exploring novel antibiotic modalities (e.g., phage therapy, antimicrobial peptides) and faces the long-term challenge of competing against generic antibiotics and the industry-wide retreat from antibiotic R&D by large pharma.